NuGen Medical Devices Inc. has announced strategic plans focused on advancing its needle-free subcutaneous drug-delivery technology. The company is progressing with the development of a Ready-to-Fill Nozzle for sterile, prefilled drug formats and is working on a next-generation variable-dose jet injector aimed at reducing training requirements and aligning with clinical practices. Efforts are underway to optimize pressure profiles for improved injection comfort and consistency, and to develop prototypes for a patented refill system designed for direct cartridge storage. NuGen is also planning the release of an animal-use injector under the PetJet™ brand. The company is expanding its clinical and technical teams in France, Brazil, Malaysia, China, and the Netherlands to support real-world evidence generation, device validation, and pharma-focused development. Engagement with distributors, clinicians, and insurance providers in markets such as the United Kingdom, Mexico, Asia, and Canada is ongoing, with plans to support global commercial activities and clinical alignment through the formation of a Medical Advisory Board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuGen Medical Devices Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 280669) on January 16, 2026, and is solely responsible for the information contained therein.